Last reviewed · How we verify

NCT04622683

Effects of Hepatic Ultrasound on Metabolic Homeostasis

Completed NA Last updated 16 December 2024
What this trial tests

NA trial testing Ultrasound in Healthy in 37 participants. Completed in 13 September 2023.

Timeline
1 January 2021
Primary endpoint
13 September 2023
13 September 2023

Quick facts

Lead sponsorYale University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment37
Start date1 January 2021
Primary completion13 September 2023
Estimated completion13 September 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

Adults 18 to 60, any sex, with Healthy or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to define the effect of ultrasound exposure of the liver in the region of the porta hepatis on glucose homeostasis and insulin resistance in healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ultrasound

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04622683.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing